Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 9/20 | 0.58 |
| ▸ | RXRB | P28702 | 6/20 | 0.58 |
| ▸ | ADH5 | P11766 | 2/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 2/20 | 0.54 |
| ▸ | RARG | P13631 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 2/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31084426 | 1.00 | RXRA (0.58) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL31084430 | 1.00 | RXRA (0.58) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL26323620 | 1.00 | RXRA (0.58) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL31628308 | 0.98 | ADH5 (0.56) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL14540358 | 0.92 | RARB (0.61) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL11507830 | 0.90 | RARB (0.63) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL3743914 | 0.87 | ALDH1A1 (0.57) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL16749653 | 0.86 | RXRA (0.59) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL7752136 | 0.85 | HSD17B1 (0.65) | RXRARXRBADH5HSD17B1RARB | |
| SCHEMBL7166892 | 0.85 | HSD17B1 (0.75) | RXRARXRBADH5HSD17B1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826426-B2 | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230293698-A1 | METAL-ORGANIC FRAMEWORKS DELIVER SMALL MOLECULES AND BIOMACROMOLECULES FOR CANCER IMMUNOTHERAPY | UNIV CHICAGO (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293698-A1 | METAL-ORGANIC FRAMEWORKS DELIVER SMALL MOLECULES AND BIOMACROMOLECULES FOR CANCER IMMUNOTHERAPY | ORC3, RBM3, RNMT | RXRA 1898/4885RXRB 2181/4885ADH5 4383/4885 |
| US-11826426-B2 | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | CD274, PDCD1LG2, PDCD1 | RXRA 157/4885RXRB 261/4885ADH5 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.